These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 34973294)

  • 1. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
    Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
    Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of
    Saeki K; Qiu W; Friedman RA; Pan S; Lu J; Ichimiya S; Chio IIC; Shawber CJ; Kitajewski J; Hu J; Su GH
    Cancer Res Commun; 2022 Dec; 2(12):1601-1616. PubMed ID: 36970723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
    Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
    Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient Rnf43 potentiates hyperactive Kras-mediated pancreatic preneoplasia initiation and malignant transformation.
    Zhou X; Sun Z; Zhang M; Qu X; Yang S; Wang L; Jing Y; Li L; Deng W; Liu F; Di J; Chen J; Wu J; Zhang H
    Animal Model Exp Med; 2022 Feb; 5(1):61-71. PubMed ID: 35229994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
    Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM; Lesinski GB
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.
    Philip B; Roland CL; Daniluk J; Liu Y; Chatterjee D; Gomez SB; Ji B; Huang H; Wang H; Fleming JB; Logsdon CD; Cruz-Monserrate Z
    Gastroenterology; 2013 Dec; 145(6):1449-58. PubMed ID: 23958541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia.
    Strickland LN; Liu W; Hussein U; Mardik N; Chen X; Mills T; Vornik LA; Savage MI; Sei S; Clifford J; Eltzschig HK; Brown PH; Zhao Z; McAllister F; Bailey-Lundberg JM
    Cancer Prev Res (Phila); 2024 Oct; 17(10):457-470. PubMed ID: 39099209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of HIPK2 attenuates KRAS
    Sozzi S; Manni I; Ercolani C; Diodoro MG; Bartolazzi A; Spallotta F; Piaggio G; Monteonofrio L; Soddu S; Rinaldo C; Valente D
    J Exp Clin Cancer Res; 2024 Sep; 43(1):265. PubMed ID: 39342278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras.
    Asahina K; Balog S; Hwang E; Moon E; Wan E; Skrypek K; Chen Y; Fernandez J; Romo J; Yang Q; Lai K; French SW; Tsukamoto H
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G265-G276. PubMed ID: 31760766
    [No Abstract]   [Full Text] [Related]  

  • 13. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
    Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
    Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28.
    Zhang S; Li P; Li J; Gao J; Qi Q; Dong G; Liu X; Jiao Q; Wang Y; Du L; Zhan H; Xu S; Wang C
    Br J Cancer; 2023 Aug; 129(3):426-443. PubMed ID: 37380804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer.
    Sun X; Yang D; Chen Y
    Cells; 2023 Nov; 12(22):. PubMed ID: 37998349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.